We purposely engineered an EpCAM aptamer with a moderate dissociation constant so that it will preferentially be enriched at the site of tumour as cancer cells express up to 1000-fold higher EpCAM than normal epithelial cells34, 35. The gene discussed is EPCAM; the disease is cancer.